Enver Aydilek

Dr. Enver Aydilek

University of Göttingen, Göttingen, Niedersachsen, Germany
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2023 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PBPhilip Bischoff
Philip Bischoff
MRMartin Reck
Martin Reck
TOTobias Overbeck
Tobias Overbeck
PCPetros Christopoulos
Petros Christopoulos
ARAchim Rittmeyer
Achim Rittmeyer
WSWolfgang Schütte
Wolfgang Schütte
PD-L1 expression currently represents the only validated predictive biomarker for immune checkpoint inhibition in metastatic non-small cell lung cancer (NSCLC) in the clinical routine, but has limited value to distinguish responses. Assessment of KRAS and TP53 mutations (mut) as surrogate for an immunosupportive tumor microenvironment (TME) might help to close this gap. 696 consecutive patients with PD-L1 high (≥50%), non-squamous NSCLC, having received molecular testing within the German National Network Genomic Medicine Lung Cancer between 2017 and 2020, with ECOG-PS ≤1 and pembrolizumab as first-line palliative treatment were included into this retrospective cohort analysis. Treatment efficacy and outcome according to KRAS/TP53 status were correlated with TME composition and gene expression analysis of the TCGA lung adenocarcinoma cohort. Proportion of KRASmut and TP53mut were 53% (G12C 25%, non-G12C 28%) and 51%, respectively. In KRASmut patients, TP53 co-mutations increased response rates (G12C: 69.7% vs. 46.5% (TP53mut vs. wt), p=0.004; non-G12C: 55.4% vs. 39.5%, p=0.03), progression-free (PFS; G12C: HR 0.59, p=0.009, non-G12C: HR 0.7, p=0.047) and overall survival (OS; G12C: HR 0.72, p=0.16, non-G12C: HR 0.56, p=0.002), whereas no differences were observed in KRASwt patients. After a median follow-up of 41 months, G12C/TP53mut patients experienced the longest PFS and OS (33.7 and 65.3 months), correlated with high TIL densities in the TME and upregulation of IFNγ target genes. Pro-inflammatory pathways according to TP53 status (mut vs. wt) were less enhanced and not different in non-G12C and KRASwt, respectively. G12C/TP53 co-mutations identify a subset of patients with a very favorable long-term survival with ICI monotherapy, mediated by highly active IFNγ signaling in a pro-inflammatory TME.

31 July 2025 in Blood Advances
Verified
Journal Article
Open access
ESEvgenii Shumilov
Evgenii Shumilov
JSJulia Katharina Scholz
Julia Katharina Scholz
MSMaximilian Seib
Maximilian Seib
PMPaolo Mazzeo
Paolo Mazzeo
RWRebecca Wurm-Kuczera
Rebecca Wurm-Kuczera
GLGeorg Lenz
Georg Lenz
Patients with large B-cell lymphoma (LBCL) who experience relapsed disease after CD19-directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapy have a poor prognosis. Bispecific antibodies (BsAbs) induce complete remissions in ∼35% of these cases. Hypothesizing overlapping LBCL-intrinsic resistance mechanisms as well as common poor prognosis predictors to CAR-T and BsAb therapy, we conducted a multicenter retrospective analysis including 92 patients with relapsed/refractory (R/R) LBCL treated with BsAbs after CAR-T failure. Overall response rate (ORR) was 43%, with a progression-free survival (PFS) of 2.8 months. Patients receiving BsAbs during early relapse (≤3 months) achieved a significantly worse outcome (ORR, 29%; PFS, 2.2 months) compared with patients with an intermediate (4-6 months; ORR, 54%; PFS, 3.7 months) or a late relapse (>6 months; ORR, 60%; PFS, 10.5 months). The benefit of later relapse was particularly notable in patients receiving BsAbs as first salvage therapy compared with those receiving a BsAb in subsequent lines (PFS not reached vs 2.7 months; overall survival not reached vs 9.1 months, respectively). In addition to early R/R state before BsAbs, elevated lactate dehydrogenase and higher International Prognostic Index score were significant predictors of poor outcomes to BsAb in multivariate Cox regression analyses. The finding that patients with early relapse after CAR-T respond particularly poorly to BsAb highlights the necessity for alternative treatment options in this high-risk patient cohort.

20 March 2024 in HemaSphere
Verified
Journal Article
Open access
PBPhilipp Berning
Philipp Berning
ESEvgenii Shumilov
Evgenii Shumilov
MMMarkus Maulhardt
Markus Maulhardt
HBHristo Boyadzhiev
Hristo Boyadzhiev
AKAndrea Kerkhoff
Andrea Kerkhoff
Thomas PabstThomas Pabst
Thomas Pabst
CD19‐directed chimeric antigen receptor (CAR)‐T cell therapy has become a standard treatment for relapsed/refractory diffuse large B‐cell lymphoma (r/r DLBCL). While the benefits of CAR‐T cell treatment are clear in the general patient population, there remains a relative scarcity of real‐world evidence regarding its efficacy and toxicity in patients (pts) aged ≥70 years with DLBCL. We conducted a multicenter retrospective analysis including 172 r/r DLBCL pts with CAR‐T cell treatment, axicabtagene ciloleucel or tisagenlecleucel, between 2019 and 2023 at three tertiary centers. Pts were grouped by age at CAR‐T infusion (<70 vs. ≥70 years). Subsequently, descriptive and survival analyses, including propensity score matching, were performed to compare outcomes between both age groups. We identified 109 pts aged <70 and 63 pts aged ≥70 years. Overall response rates for both age groups were comparable (77.7% vs. 78.3%; p = 0.63). With a median follow‐up of 8.3 months, median progression‐free survival was 10.2 months (95% confidence interval [CI]: 6.5–21.8) and 11.1 months (95% CI: 4.9–NR) (p = 0.93) for both cohorts. Median overall survival reached 21.8 months (95% CI: 11.8–NR) and 34.4 months (95% CI: 10.1–NR) (p = 0.97), respectively. No significant differences in the incidence of cytokine release syndrome (p = 0.53) or grade ≥3 neurotoxicity (p = 0.56) were observed. Relapse and nonrelapse mortality were not significantly different between both groups. Our findings provide additional support that CAR‐T cell therapy is feasible and effective in patients with r/r DLBCL aged 70 years or older, demonstrating outcomes comparable to those observed in younger patients. CAR‐T cell therapy should be not withheld for elderly patients with r/r DLBCL.

28 November 2023 in Blood
Verified
Journal Article
Open access
GHGeorg Hess
Georg Hess
VVVladan Vucinic
Vladan Vucinic
KRKai Rejeski
Kai Rejeski
EAEnver Aydilek
Enver Aydilek
LSLinda Simon
Linda Simon
PDPeter Dreger
Peter Dreger
Background: Chimeric antigen receptor T-cells have revolutionized treatment in many B-cell neoplasias. In MCL, brexucabtagene autoleucel (brexu-cel) has been the first product approved based on results of the ZUMA-2 trial for patients failing prior chemoimmunotherapy and BTK-inhibitor. However, in ZUMA-2, strict criteria have been used for patient selection, e.g. no use of intensive bridging/holding treatment was allowed, excluding patients with high treatment needs. In contrast to this, in the real-world scenario patient selection is much more diverse questioning whether the results of controlled trials can be reproduced in the regular treatment landscape. In this intent, we have analyzed the results obtained with brexu-cel as standard-of-care treatment (SOC) of r/r MCL in Germany and Switzerland. Patients/methods: Eligible for this first analysis of an ongoing registry study were all German and Swiss patients with r/r MCL who have been treated with SOC brexu-cel since 09/2020 and were registered with the German Stem Cell Registry (DRST) and the Registry of the European Mantle Cell lymphoma (EMCL), respectively. Of note, some patients have received more than one CAR-T-treatment. Data were analyzed for patient and disease characteristics, prior treatment history, response to treatment, and complications as well as post treatment outcomes. Due to the character of this analysis based on real world data, with heterogeneous surveillance strategies we have used primarily time to next treatment (TTNT) instead of progression-free survival, due to the potential biases for the latter. While still adding patients to the analysis, an additional follow-up data cut is planned 10/2023. Results: 111 patients have been identified: median age at diagnosis was 64.3 years (range 42.3-79.5; 19/99 patients ≥ 70), 18% female (not known (nk) 2.7%); ethnicity 66.7% Caucasian (nk 30.6%). Disease characteristics: 80/88 had stage 3/4 (91%), histology was classical in 34/57 cases (60%) and blastoid in 19/57 (33%), respectively. MIPI score was low 14/53 (26%), intermediate 17 (32%), high 21 (40%). TP53 alteration was present in 13/58 (22%), Ki67-expression was ≤ 30% in 18/50 (36%). TTNT for last treatment preceding CAR-T-treatment was 7.7 months. Overall survival (OS) for the entire patient population from diagnosis was 12.8 years. Preceding CAR-T, median number of treatments was 3 (range 1-9), all patients had prior Rituximab and Ibrutinib, 62 patients (56%) had received autologous stem cell transplantation (SCT) and 11 patients had received an allogeneic SCT. Median age at this time point was 68.1 years (range 49-82y). 50/110 patients were >70 years. Bridging treatment had been used in 88/112 (79%) preceding CAR. Based on investigator evaluation ORR was 86%, best response to CAR-T was CR in 47/76 patients (62%) and PR in 18/76 (24%). Time to death or new treatment after CAR-T was 8 months (mo) for patients ≤ 70y and 12 mo for patients > 70y. There was no difference for the number of prior lines (≤ 3 vs. > 3). The estimated median OS was 1.9 years. 26 patients have received at least 1 additional line of treatment after progression. Safety: Post-CAR CRS was seen in 95/114 (83%), Grade 1/2 77/95 (81%), Grade 3/4 (18%), Grade 5 (1%); ICANS was noted in 57/111 (51%), Grade 1/2 43/57 (75%), all other Grade 3/4. The rate of ICU admissions was 25/106 (24%). However, within 28 days after CAR-T-cell treatment 9/98 (9%) patients have died. Overall, in the post CAR-T-period 20 patients died of reasons other than progression: 4 CAR-related, 11 infections, 5 other/unknown. Discussion: In this real-world analysis, we could demonstrate, despite a more heterogeneous pre-treated patient population, a high overall and complete response rate. Median post CAR-T-cell survival was promising with 1.9 years. While CRS and ICANS risks seem to be comparable to trial data, the high non-relapse mortality (NRM) observed after SOC brexu-cel for r/r MCL is a concern and warrants refinement of anti-infectious surveillance and prophylaxis. Further work focusses on the identification of potential risk factors, e.g. using risk scores such as CAR-HAEMATOTOX, EASIX, and Severe4. Hess:Novartis: Consultancy; Roche: Consultancy, Honoraria; Miltenyi: Consultancy; ADC Therapeutics: Consultancy, Honoraria; Lilly: Consultancy, Honoraria; Astra: Consultancy, Honoraria; Morphosys: Research Funding; Incyte: Consultancy, Honoraria, Research Funding; BMS: Consultancy; Janssen: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Kite/Gilead: Consultancy, Honoraria, Research Funding. Vucinic:Takeda: Consultancy, Honoraria; MSD: Consultancy, Honoraria; Sobi: Honoraria, Other: Travel/Accommodations/Expenses; Amgen: Honoraria; AstraZeneca: Honoraria; Janssen: Honoraria; Gilead/Kite: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria, Other: Travel/Accommodations/Expenses; Novartis: Consultancy, Honoraria; Abbvie: Honoraria. Rejeski:Kite/Gilead: Other: Travel Support, Research Funding; Novartis: Honoraria; BMS/CELGENE: Consultancy, Honoraria; Pierre-Fabre: Other: Travel Support. Penack:Gilead, Jazz, MSD, Novartis, Pfizer and Therakos: Honoraria, Other: Travel support; Incyte and Priothera: Research Funding; Equillium Bio, Jazz, Gilead, Novartis, MSD, Omeros, Priothera, Sanofi, Shionogi and SOBI: Membership on an entity's Board of Directors or advisory committees. Koenecke:Pierre Fabre: Consultancy; Kite/Gilead: Consultancy; Sanofi-Aventis: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Miltenyi Biotec: Consultancy; Roche: Consultancy, Speakers Bureau; Pfizer: Consultancy; Novartis: Consultancy, Speakers Bureau; Medigene: Consultancy; Amgen: Consultancy; Glaxo Smith Kline: Consultancy; BMS: Consultancy. von Bonin:Janssen: Research Funding; BMS: Other: Advisory Board; Novartis: Other: Advisory Board; Kite: Other: Advisory Board. von Tresckow:Pfizer: Consultancy; Amgen: Consultancy; Roche: Consultancy, Honoraria, Other: Travel Support; Pentixapharm: Consultancy; Noscendo: Consultancy; Gilead Kite: Consultancy, Other: Travel Support; Incyte: Consultancy, Honoraria; Cerus: Consultancy; MSD: Consultancy, Honoraria, Other: Travel Support, Research Funding; AbbVie: Other: Travel Support; AstraZeneca: Honoraria, Other: Travel Support; Lilly: Consultancy, Honoraria, Other: Travel Support; Pierre Fabre: Other: Travel support; Miltenyi: Consultancy; IQVIA: Consultancy; BMS/Celgene: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Other: Travel Support, Research Funding; Allogene: Consultancy; Takeda: Consultancy, Honoraria, Other: Travel Support, Research Funding. Stilgenbauer:Abbvie: Consultancy, Honoraria, Other: travel support, Research Funding; Sunesis: Consultancy, Honoraria, Other: travel support, Research Funding; Celgene: Consultancy, Honoraria, Other: travel support, Research Funding; Gilead: Consultancy, Honoraria, Other: travel support, Research Funding; GSK: Consultancy, Honoraria, Other: travel support, Research Funding; Roche: Consultancy, Honoraria, Other: travel support, Research Funding; Janssen: Consultancy, Honoraria, Other: travel support, Research Funding; Novartis: Consultancy, Honoraria, Other: travel support, Research Funding; AstraZeneca: Consultancy, Honoraria, Other: travel support, Research Funding; Amgen: Consultancy, Honoraria, Other: travel support, Research Funding. Schroers:BMS: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; GSK: Consultancy, Honoraria. Duell:MorphoSys AG, Regeneron: Research Funding. Mueller:AstraZeneca, BMS, Gilead, Janssen, Miltenyi biomedicine, Novartis: Consultancy; Miltenyi, BMS, Novartis, Gilead, Janssen, Incyte, AstraZeneca, Abbvie, Sobi, Beigene: Honoraria; BMS, AstraZeneca, Gilead: Research Funding. Kerkhoff:AbbVie, Amgen, Zeneca: Honoraria; Roche,Sobi: Honoraria; Takeda: Honoraria; BeiGene, BMS, pharma: Honoraria. Dreyling:Astra Zeneca, Beigene, Gilead/Kite, Janssen, Lilly, Novartis, Roche: Honoraria; Abbvie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Roche: Research Funding; Abbvie, Astra Zeneca, Beigene, BMS/Celgene, Gilead/Kite, Janssen, Lilly/Loxo, Novartis, Roche: Other: Scientific advisory boards. Dreger:Gilead: Consultancy, Speakers Bureau; BMS: Consultancy, Honoraria; Novartis: Consultancy, Speakers Bureau; Riemser: Consultancy, Research Funding, Speakers Bureau; Roche: Consultancy, Speakers Bureau; Beigene: Consultancy, Honoraria; AstraZeneca: Consultancy, Speakers Bureau; Abbvie: Consultancy, Speakers Bureau; Miltenyi: Consultancy.

29 August 2023 in HemaSphere
Verified
Journal Article
Open access
EAEnver Aydilek
Enver Aydilek
SKSusanne Klein-Scory
Susanne Klein-Scory
JTJulia Thomson
Julia Thomson
VNVerena Nilius-Eliliwi
Verena Nilius-Eliliwi
DVDeepak Vangala
Deepak Vangala
TMThomas Mika
Thomas Mika

19 September 2025 in Leukemia
Verified
Journal Article
Open access
PDF file
PMPaolo Mazzeo
Paolo Mazzeo
SPSarah Mae Penir
Sarah Mae Penir
ESEvgenii Shumilov
Evgenii Shumilov
SWSebastian Wolf
Sebastian Wolf
BHBjörn Häupl
Björn Häupl
RKRaphael Koch
Raphael Koch
Treatment of high-risk Myelodysplastic Neoplasms (hr-MDS) and (secondary) Acute Myeloid Leukemia (AML) remains a clinical challenge. The combination of azacitidine and venetoclax (aza/ven) may improve treatment outcomes, but still fails in a significant fraction of patients. We established a single-center collection of longitudinal samples from patients with MDS and AML/sAML and performed comprehensive genetic, proteomic and functional apoptosis profiling to identify biomarkers and targetable escape mechanisms to aza/ven. Baseline genetic characterization ( n = 55) identified high-risk genetic alterations, while longitudinal analyses ( n = 268, mean 8.7 [3–20] timepoints) revealed distinct genetic profiles of clonal evolution. Functional BH3-profiling at treatment initiation identified heterogeneous dependencies on BCL-2 family members. Notably, high BCL-2 dependence correlated with genetic response to aza/ven and improved overall survival, whereas increased BCL-xL dependence was associated with resistance. We further identified patterns of acquired resistance, with loss of apoptotic priming and shifts in anti-apoptotic dependencies contributing to treatment failure. BH3 profiling revealed functional shifts toward MCL-1 and/or BCL-xL in individual cases, suggesting potential therapeutic targets to overcome resistance. In vitro, BCL-xL inhibition effectively counteracted resistance in increased BCL-xL dependence cases. In summary, we characterized treatment-associated clonal evolution in MDS and AML, providing insights into clinical response, disease progression and potential individualized therapeutic strategies.